|
|
Volumn 140, Issue 18, 2019, Pages 1448-1450
|
|
More credence for SGLT2 inhibition
|
|
Author keywords
Cardiovascular diseases; Chronic; Diabetes mellitus; Diabetic nephropathies; Kidney failure
|
|
Indexed keywords
GLUCAGON LIKE PEPTIDE 1;
GLUCAGON LIKE PEPTIDE 1 RECEPTOR;
SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;
ANTIDIABETIC AGENT;
SODIUM GLUCOSE COTRANSPORTER 2;
BLOOD PRESSURE;
CAUSE OF DEATH;
DEATH;
DISEASE COURSE;
DRUG EFFECT;
EDITORIAL;
END STAGE RENAL DISEASE;
FOLLOW UP;
GLOMERULUS FILTRATION RATE;
GLUCOSE TRANSPORT;
GLYCEMIC CONTROL;
HEART FAILURE;
HOSPITALIZATION;
HYPERKALEMIA;
INSULIN DEPENDENT DIABETES MELLITUS;
KIDNEY BLOOD FLOW;
KIDNEY FUNCTION;
PRIORITY JOURNAL;
RENAL PROTECTION;
RENAL REPLACEMENT THERAPY;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
RISK REDUCTION;
ADULT;
AGED;
DIABETIC NEPHROPATHY;
GLUCOSE BLOOD LEVEL;
HUMAN;
KIDNEY;
MIDDLE AGED;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PHARMACOLOGY;
ADULT;
AGED;
BLOOD GLUCOSE;
DIABETES MELLITUS, TYPE 2;
DIABETIC NEPHROPATHIES;
HUMANS;
HYPOGLYCEMIC AGENTS;
KIDNEY;
MIDDLE AGED;
SODIUM-GLUCOSE TRANSPORTER 2;
SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;
|
|
EID: 85074242129
PISSN: 00097322
EISSN: 15244539
Source Type: Journal
DOI: 10.1161/CIRCULATIONAHA.119.041181 Document Type: Editorial |
|
Times cited : (15)
|
|
References (5)
|
